awareness

There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.

results

Our preliminary Phase 3 data show Vicinium® is very well-tolerated and with demonstrated efficacy in patients with high-grade NMIBC.

Read our Phase 3 Trial Progress and Updates

innovation

Vicinium is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates.

bringing new hope for treating bladder cancer

Vicinium is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicinium has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 17% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.

LEARN MORE
white-border-top

BLADDER CANCER

stat-ring

6th

most common cancer

stat-ring

72

average age of diagnosis

stat-ring

80,000+

new cases each year in the U.S.

stat-ring

$4 billion

annual costs

white-border-top

RENEW LIFE

change lives with us

We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.

learn more
Top